Sanofi
- Company typePublic
- Founded2004
- HeadquartersWarszawa, Poland
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Sanofi firmographics
Firmographics- Name
- Sanofi
- Legal name
- Sanofi Sp. z o.o.
- Website
- https://sanofi.pl
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Sanofi industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)
- akta.pro secondary industries
- Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN), Public & Private Vaccine Provider Networks (Clinics/Pharmacies/Physicians) (HLAJAHAB)
Keywords
Where Sanofi is headquartered
LocationHeadquarters
- HQ city
- Warszawa
- HQ country
- Poland
- HQ region
- Europe
Offices3 records
Markets served
Sanofi business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
Revenue model
- Pharmaceutical Products: Revenue from prescription pharmaceutical products across multiple therapeutic areas including immunology, oncology, and specialty care.
- Vaccines: Seasonal influenza vaccines (VaxigripTetra) and other vaccines for public health protection, supplied annually based on vaccination rates and country demand.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Sanofi product offering
Product offeringCore offering
Sanofi Polska develops, manufactures, and distributes pharmaceutical products and vaccines across five therapeutic areas, leveraging AI-integrated immunology science. Its most visible offerings include the VaxigripTetra seasonal influenza vaccine and Plavix antiplatelet medication, supplied via direct sales to pharmacies and hospitals through its Warsaw customer service, Rzeszów production site, and Błonie wholesale center. The company also supports the Campus Sanofi educational platform for physicians and runs patient support programs and rare disease awareness campaigns.
Product overview
Sanofi is an innovative biopharma company that operates across 5 therapeutic areas and has 93 substances in clinical development phase, with 26 clinical trials in phase 3. The company combines science with AI technology to develop and deliver pharmaceutical products and vaccines. Key products include VaxigripTetra® (influenza vaccine) and Plavix (prescription medication). Sanofi also operates Campus Sanofi, an educational platform for medical professionals. The company is positioned as a pioneer in immunology with over 50 years of experience, from the first polio vaccine to cutting-edge biological therapies.
Differentiator
Problem solved
Functional benefit
Brands
- VaxigripTetra: Influenza vaccine produced by Sanofi for seasonal flu protection.
Products and services
- VaxigripTetra Seasonal influenza vaccine produced by Sanofi for flu protection, supplied annually to Polish pharmacies, hospitals, and public health programs based on vaccination rates and country demand.
- Plavix Prescription antiplatelet medication available for ordering by pharmacies and hospitals through Sanofi's dedicated customer service line (222 800 980).
- Campus Sanofi Professional development and education platform for physicians and medical professionals to advance their knowledge and skills, operated at campus.sanofi/pl.
- Polish Atopic Disease Society Support Hotline (PTCA) Patient support hotline supported by Sanofi that provides patients with atopic diseases, their caregivers, and physicians access to information on reimbursed atopic dermatitis (AZS) therapies and free consultations with psychology, dietetics, and AZS therapy experts.
Quantifiable outcome
- 93 substances in clinical development pipeline
- +2 more outcomes
Companies that use Sanofi
Customer profileSegments3 records
Ideal customer profiles3 records
Sanofi technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature2 records
Sanofi partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Fundacja Ronalda McDonalda (Ronald McDonald Foundation)minorLocal partner of the WeVolunteer employee volunteering program. Sanofi volunteers supported the Ronald McDonald House and UCK WUM Pediatric Hospital, providing assistance to parents of neonatology and rare disease patients, as well as families of oncology and hematology patients.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Sanofi competitors and assessment
Company assessmentDirect peers
- GlaxoSmithKline (GSK) Poland: GSK's Polish subsidiary is a direct peer, competing head-to-head with Sanofi Polska in seasonal influenza vaccines and a broad pharmaceutical/vaccine portfolio supplied through the same pharmacy and hospital channels in Poland.
- Pfizer Poland: Pfizer's Polish subsidiary competes directly with Sanofi Polska across prescription pharmaceuticals, vaccines (including COVID and flu), and specialty/biological therapies, sharing similar hospital and pharmacy distribution channels in Poland.
- Roche Poland: Roche Poland is a direct peer in specialty pharmaceuticals and biologics, operating through similar hospital procurement channels and competing with Sanofi Polska in immunology and rare disease therapeutic areas in Poland.
- Novartis Poland: Novartis Poland competes with Sanofi Polska in prescription specialty pharmaceuticals, immunology, and rare disease treatments, accessing the same Polish hospital and reimbursement ecosystem.
- AstraZeneca Poland: AstraZeneca Poland is a direct peer in biopharmaceuticals and vaccines, with overlapping therapeutic area focus and shared hospital/pharmacy distribution channels in the Polish market.
- Merck Sharp & Dohme (MSD) Poland: MSD Poland competes with Sanofi Polska in vaccines and specialty pharmaceuticals, including HPV and oncology portfolios, using comparable medical information and hospital account management approaches in Poland.
- Johnson & Johnson Poland: J&J Poland's pharmaceutical division competes with Sanofi Polska in immunology, rare disease, and specialty care therapeutic areas through the same hospital, pharmacy, and physician channels.
- Seqirus (CSL): Seqirus is a direct peer in seasonal and pandemic influenza vaccines, directly competing with Sanofi's VaxigripTetra franchise for tender and procurement share across European markets including Poland.
Emerging players
- Moderna: Moderna is an emerging peer in mRNA-based vaccines, including influenza, that competes with Sanofi's flu vaccine franchise and is building European commercial presence that will increasingly overlap with Sanofi Polska's market.
Regional players
- Polfa Tarchomin: Polfa Tarchomin is a domestic Polish pharmaceutical manufacturer and competitor, overlapping with Sanofi Polska in prescription medicines distributed through Polish pharmacies and hospitals, though with a narrower product range.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Sanofi social profiles
Digital presenceSanofi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanofi leadership team
Management profileNumber of profiles
Profiles1 record
Sanofi funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanofi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanofi
What does Sanofi do?
Sanofi Polska develops, manufactures, and distributes pharmaceutical products and vaccines across five therapeutic areas, leveraging AI-integrated immunology science. Its most visible offerings include the VaxigripTetra seasonal influenza vaccine and Plavix antiplatelet medication, supplied via direct sales to pharmacies and hospitals through its Warsaw customer service, Rzeszów production site, and Błonie wholesale center. The company also supports the Campus Sanofi educational platform for physicians and runs patient support programs and rare disease awareness campaigns.
Is Sanofi a public or private company?
Sanofi is a public company. It is classified as public and is currently operating.
When was Sanofi founded?
Sanofi was founded in 2004. It employs 1,001 to 5,000 people.
Where is Sanofi based?
Sanofi is headquartered in Warszawa, Poland, in the Europe region.
How does Sanofi make money?
Two revenue lines are on record. Pharmaceutical Products are the primary driver. The others are vaccines.
Who are Sanofi's main competitors?
Direct peers on record are GlaxoSmithKline (GSK) Poland, Pfizer Poland, Roche Poland, Novartis Poland, AstraZeneca Poland, Merck Sharp & Dohme (MSD) Poland, Johnson & Johnson Poland and Seqirus (CSL). Moderna is listed as an emerging player. Polfa Tarchomin is listed as a regional player.
Does Sanofi have an API?
No public API is recorded for Sanofi.
What industry is Sanofi in?
Sanofi's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult), with a secondary code of HLAIAEAN, Vaccine Procurement, Tendering & Immunization Supply Programs. Its NAICS code is 325412 and its SIC code is 2834.